Navigation Links
Study demonstrates link between reclassification of cannabis and cannabis psychosis
Date:7/18/2013

Researchers from the University of York have demonstrated that the change in cannabis declassification in 2009 has coincided with a significant increase in hospital admissions for cannabis psychosis - rather than the decrease it was intended to produce.

The UK Misuse of Drugs Act (1971) divided controlled drugs into three groups A, B and C with descending criminal sanctions attached to each class. Cannabis was originally assigned to Group B, but in 2004, it was transferred to the lowest risk group, Group C.

In 2009, on the basis of increasing concerns about a link between high strength cannabis and schizophrenia, it was moved back to Group B.

Researchers from the University's Department of Health Sciences examined admissions to psychiatric hospitals in England between 1999 and 2010 to explore whether the reclassifications in 2004 and 2009 were associated with changes in the admissions rate for cannabis psychosis.

They found that there was a significantly increasing trend in admissions from 1999 to 2004, but following the reclassification of cannabis from B to C in 2004, there was a decline until 2009. Following the second reclassification back to class B in 2009, there was once again a significant increase in admissions.

The study was led by Ian Hamilton from York's Department of Health Sciences, an expert on the relationship between substance misuse and mental health. The results are published in the International Journal of Drug Policy.

Psychosis describes a range of symptoms, such as distortions of reality, hearing voices, difficulty in thinking and problems with motivation.

Ian Hamilton said: "Our research shows an interesting relationship between the Government's decision to reclassify cannabis and the rate of hospital admissions for cannabis psychosis. It is significant as the Government's argument for reclassification was made on the basis that the stronger forms of cannabis known as 'skunk' are more likely to lead to mental health problems such as psychosis. However, our research challenges this.

"While our study shows a statistical association between the reclassification of cannabis and hospital admissions for cannabis psychosis, it is in the opposite direction to that predicated by the presumed relationship between the two."

The authors say the reasons for the statistical association between the reclassification of cannabis and hospital admissions for cannabis psychosis are unclear.

Ian Hamilton said: "The association is unlikely to be due to changes in cannabis use over this period, but possible explanations include changes in policing and systematic changes in mental health services unrelated to classification decisions."


'/>"/>

Contact: Caron Lett
caron.lett@york.ac.uk
44-019-043-22029
University of York
Source:Eurekalert

Related medicine news :

1. Spectrum Health study first to identify heart attack-causing plaque in living patients
2. TGen-TD2-Scottsdale Healthcare breast cancer pilot study shows value of proteomic mapping
3. Study of Vanuatu Further Identifies Behaviors That Cause Obesity
4. Study reveals new dietary risk factors for colorectal cancer
5. Undiagnosed pre-diabetes highly prevalent in early Alzheimers disease study
6. Pradaxa Lawsuit News: Bernstein Liebhard LLP Notes New Study Linking Pradaxa to Increased Heart Attack Risk
7. Advanced Medical Certification Offers Audiobooks and PDF Study Guides at No Cost Upon Course Purchase
8. Biomarker Market is Estimated to Grow at a CAGR of 14.40% During the Study Period of 2011-2016 – New Report by MarketsandMarkets
9. Besttoolbars Study Reveals New Trend in Online Cashback Marketing
10. Study finds strong pregnancy outcomes for survivors of childhood cancer
11. Study finds potential markers for severity of childhood arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... With over 16,000 ... bioidentical hormone replacement therapy and integrative medicine, has become a frontrunner for people ... such as menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded in ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage ... up its marketing efforts with its product now available through Jet.com. , After ... public. The effervescent powdered drink is designed to quickly detox the body thereby avoiding ...
(Date:8/18/2017)... ... 2017 , ... 800response, the leading provider of dynamic call-to-action ... launch of a redesigned corporate website, 800response.com . , Key features ... an enhanced search directory for businesses and advertising agencies to use to ...
(Date:8/18/2017)... ... ... “Dangerous Inheritance”: a mystery about saving the family farm. “Dangerous Inheritance” ... where she was raised on a farm. As Diane wrote this story, she ... friendships and mantra of ‘neighbors helping neighbors’ have always been a large part of ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Beyond Our Imaginations: The Infinite God”: shows the ... Infinite God” is the creation of published author, Mark Lawrence, born in Michigan, the ... “The problem with becoming a greater man of God is that I have to ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... International plc (NASDAQ: ENDP ) today announced that ... U.S. mesh product liability claims and that it is ... claims at reasonable values. Under the agreements, Endo will ... 2017 and continuing through the fourth quarter of 2019. ... Company intends to increase its mesh product liability accrual ...
(Date:8/2/2017)... 2, 2017 Fenita J. Caldwell ... a Pinnacle Lifetime Professional in the Field of ... at Turing Pharmaceuticals, AG. Her skills and areas ... building.                ... years of experience as a highly successful sales ...
(Date:8/1/2017)... --  CerSci Therapeutics , a non-opioid drug development firm ... received notice from the National Institute on Drug Abuse ... it has been awarded a Direct-to-Phase II Small Business ... with an additional $1,000,000 to follow in 2018. These ... their lead non-opioid drug candidate CT-044 to the Food ...
Breaking Medicine Technology: